SCLT1

Across TCGA pan-cancer cohorts, SCLT1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SCLT1 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SCLT1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SCLT1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where SCLT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.984	0.422	.024	10	view →
CCRCC	OS	Median	All	0.967	0.741	.011	10	view →
UCEC	DFS	Median	All	0.965	0.842	.020	4	view →
HNSC	DFS	Median	III,IV	0.406	0.707	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SCLT1–PDAC (OS)

Open the PDAC breakdown →